Valneva SE VALN recently applied for a label extension to the FDA to potentially extend the use of its chikungunya vaccine, IXCHIQ. Currently approved for adults, the vaccine may soon be accessible to ...
To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), November 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, ...